Scancell Holdings plc (LON:SCLP - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 13.76 ($0.17) and traded as low as GBX 10 ($0.12). Scancell shares last traded at GBX 10 ($0.12), with a volume of 906,872 shares.
Scancell Stock Down 4.8 %
The company has a market cap of £92.96 million, a P/E ratio of -1,000.00 and a beta of 0.35. The company's 50-day moving average is GBX 12.63 and its two-hundred day moving average is GBX 13.74. The company has a debt-to-equity ratio of 61.41, a current ratio of 3.42 and a quick ratio of 13.01.
Scancell Company Profile
(
Get Free Report)
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Featured Stories
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
